PTGX
Protagonist Therapeutics, Inc. NASDAQ Listed Aug 11, 2016$112.86
+1.27%
vs $111.44
Mkt Cap $7.2B
52w Low $49.70
100.0% of range
52w High $112.86
50d MA $102.30
200d MA $87.50
P/E (TTM)
-55.0x
EV/EBITDA
—
P/B
11.7x
Debt/Equity
0.0x
ROE
-21.2%
P/FCF
127.9x
RSI (14)
66.40
ATR (14)
$4.89
Beta
2.11
50d MA
$102.30
200d MA
$87.50
Avg Volume
610.1K
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
7707 Gateway Boulevard · Newark, CA 94560-1160 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.65 | 0.06 | +109.2% | 103.97 | -0.4% | -4.9% | +0.5% | +4.2% | -3.4% | +3.9% | — |
| Feb 25, 2026 | AMC | -0.53 | -0.69 | -30.2% | 87.10 | +0.5% | +1.5% | +4.2% | +2.3% | -3.1% | +3.9% | — |
| Nov 6, 2025 | AMC | -0.59 | -0.62 | -5.1% | 79.78 | +0.4% | -0.3% | +4.6% | +2.8% | -0.8% | -1.9% | — |
| Aug 6, 2025 | AMC | -0.53 | -0.55 | -3.8% | 53.87 | +0.5% | -5.4% | +0.2% | +5.2% | +1.5% | +4.0% | — |
| May 6, 2025 | AMC | -0.50 | -0.19 | +62.0% | 42.01 | -0.6% | +2.6% | +1.9% | -2.2% | +5.4% | -2.2% | — |
| Feb 21, 2025 | AMC | 0.06 | 1.98 | +3200.0% | 38.75 | +0.0% | -7.1% | -2.5% | +3.0% | +0.5% | +3.4% | — |
| Nov 7, 2024 | AMC | -0.59 | -0.54 | +8.5% | 47.61 | +2.6% | -2.9% | +0.6% | -7.2% | -1.2% | -3.8% | — |
| Aug 6, 2024 | AMC | -0.50 | -0.50 | +0.0% | 36.21 | +1.2% | -1.2% | +3.9% | +4.1% | +4.9% | -0.7% | — |
| May 7, 2024 | AMC | 1.19 | 3.26 | +173.9% | 25.79 | +5.0% | +5.1% | +4.3% | -0.1% | +3.9% | +1.0% | — |
| Feb 27, 2024 | AMC | 0.03 | 0.44 | +1425.3% | 29.59 | +1.4% | +2.8% | -0.2% | +5.8% | -1.6% | -2.2% | — |
| Nov 2, 2023 | AMC | -0.68 | -0.58 | +14.7% | 15.41 | +2.3% | +8.0% | -2.2% | +1.1% | -3.0% | -5.8% | — |
| Aug 3, 2023 | AMC | -0.65 | -0.68 | -4.6% | 18.57 | -0.2% | +3.3% | -1.3% | -3.9% | +0.2% | +3.1% | — |
| May 4, 2023 | AMC | -0.69 | -0.67 | +2.9% | 23.60 | +4.8% | +5.1% | +0.5% | +1.3% | -0.9% | -1.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 21 | Wolfe Research | Initiates | Outperform | $135 | $100.88 | $101.13 | +0.2% | +1.1% | -2.8% | +0.8% | +2.2% | -1.8% |
| Apr 15 | Truist | Maintains | Buy → Buy | — | $104.72 | $105.96 | +1.2% | +0.7% | -1.6% | +2.2% | -0.5% | +0.4% |
| Apr 7 | Clear Street | Maintains | Buy → Buy | — | $102.89 | $103.43 | +0.5% | +0.8% | -1.6% | +2.0% | -5.1% | -1.3% |
| Mar 19 | Barclays | Maintains | Overweight → Overweight | — | $97.09 | $98.45 | +1.4% | +4.7% | -2.8% | -0.3% | +1.9% | +3.9% |
| Mar 19 | Leerink Partners | Maintains | Outperform → Outperform | — | $97.09 | $98.45 | +1.4% | +4.7% | -2.8% | -0.3% | +1.9% | +3.9% |
| Mar 19 | JP Morgan | Maintains | Overweight → Overweight | — | $97.09 | $98.45 | +1.4% | +4.7% | -2.8% | -0.3% | +1.9% | +3.9% |
| Mar 19 | Citigroup | Maintains | Buy → Buy | — | $97.09 | $98.45 | +1.4% | +4.7% | -2.8% | -0.3% | +1.9% | +3.9% |
| Mar 3 | Goldman Sachs | Maintains | Neutral → Neutral | — | $94.24 | $92.56 | -1.8% | -3.1% | +3.9% | -3.6% | +0.7% | +5.0% |
| Feb 26 | Barclays | Maintains | Overweight → Overweight | — | $87.10 | $87.50 | +0.5% | +1.5% | +4.2% | +2.3% | -3.1% | +3.9% |
| Feb 26 | TD Cowen | Maintains | Buy → Buy | — | $87.10 | $87.50 | +0.5% | +1.5% | +4.2% | +2.3% | -3.1% | +3.9% |
| Feb 26 | Citizens | Maintains | Market Outperform → Market Outperform | — | $87.10 | $87.50 | +0.5% | +1.5% | +4.2% | +2.3% | -3.1% | +3.9% |
| Feb 2 | Jefferies | Maintains | Buy → Buy | — | $81.80 | $81.80 | +0.0% | +1.5% | +3.1% | -2.7% | -3.2% | +4.7% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $79.73 | $79.77 | +0.1% | +2.6% | +1.5% | +3.1% | -2.7% | -3.2% |
| Jan 5 | Truist | Maintains | Buy → Buy | — | $87.18 | $87.53 | +0.4% | -3.4% | -2.3% | +0.1% | -2.6% | +0.0% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $91.54 | $91.41 | -0.1% | -2.4% | -4.0% | +0.3% | +1.6% | +1.5% |
| Dec 8 | Citigroup | Maintains | Buy → Buy | — | $89.65 | $90.94 | +1.4% | +0.7% | -1.9% | +3.2% | +1.0% | +3.4% |
| Nov 10 | Citigroup | Maintains | Buy → Buy | — | $79.54 | $80.58 | +1.3% | +4.6% | +2.8% | -0.8% | -1.9% | +1.6% |
| Nov 7 | Barclays | Maintains | Overweight → Overweight | — | $79.78 | $80.12 | +0.4% | -0.3% | +4.6% | +2.8% | -0.8% | -1.9% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $79.78 | $80.12 | +0.4% | -0.3% | +4.6% | +2.8% | -0.8% | -1.9% |
| Nov 7 | Citizens | Maintains | Market Outperform → Market Outperform | — | $79.78 | $80.12 | +0.4% | -0.3% | +4.6% | +2.8% | -0.8% | -1.9% |
| Oct 28 | Wedbush | Maintains | Outperform → Outperform | — | $75.25 | $75.06 | -0.3% | +4.3% | -2.3% | +1.5% | +1.0% | -3.4% |
| Oct 28 | Truist | Maintains | Buy → Buy | — | $75.25 | $75.06 | -0.3% | +4.3% | -2.3% | +1.5% | +1.0% | -3.4% |
| Oct 28 | BTIG | Maintains | Buy → Buy | — | $75.25 | $75.06 | -0.3% | +4.3% | -2.3% | +1.5% | +1.0% | -3.4% |
| Oct 17 | Citigroup | Maintains | Buy → Buy | — | $75.73 | $75.60 | -0.2% | +2.3% | -1.0% | -2.2% | -2.0% | +0.7% |
| Oct 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $65.47 | $65.28 | -0.3% | -0.3% | +2.7% | +29.8% | -9.0% | -2.8% |
| Sep 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $58.59 | $60.05 | +2.5% | +1.1% | +4.9% | +0.1% | +3.7% | +0.9% |
| Aug 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $53.87 | $54.12 | +0.5% | -5.4% | +0.2% | +5.2% | +1.5% | +4.0% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $50.15 | $49.91 | -0.5% | +1.8% | +0.9% | +4.4% | +1.0% | +2.4% |
| May 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.49 | $44.45 | -0.1% | +2.4% | +2.3% | -1.7% | +0.2% | -0.5% |
| Apr 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $42.57 | $41.44 | -2.7% | -3.9% | +4.2% | +5.7% | +4.3% | -2.4% |
| Mar 28 | Wedbush | Maintains | Outperform → Outperform | — | $49.44 | $49.47 | +0.1% | -1.1% | -1.1% | -3.1% | +2.8% | -3.5% |
| Mar 11 | BMO Capital | Maintains | Outperform → Outperform | — | $55.95 | $55.90 | -0.1% | +6.8% | -3.5% | -4.8% | -0.2% | -3.2% |
| Mar 11 | Truist | Maintains | Buy → Buy | — | $55.95 | $55.90 | -0.1% | +6.8% | -3.5% | -4.8% | -0.2% | -3.2% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $55.95 | $55.90 | -0.1% | +6.8% | -3.5% | -4.8% | -0.2% | -3.2% |
| Mar 10 | Citizens Capital Markets | Maintains | Market Outperform → Market Outperform | — | $38.35 | $50.08 | +30.6% | +45.9% | +6.8% | -3.5% | -4.8% | -0.2% |
| Mar 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.35 | $50.08 | +30.6% | +45.9% | +6.8% | -3.5% | -4.8% | -0.2% |
| Mar 4 | JP Morgan | Maintains | Overweight → Overweight | — | $38.50 | $38.24 | -0.7% | +0.4% | -0.5% | +1.6% | -1.8% | +45.9% |
| Mar 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.59 | $40.81 | +8.6% | +2.4% | +0.4% | -0.5% | +1.6% | -1.8% |
| Feb 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $38.75 | $38.75 | +0.0% | -7.1% | -2.5% | +3.0% | +0.5% | +3.4% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $38.75 | $38.75 | +0.0% | -7.1% | -2.5% | +3.0% | +0.5% | +3.4% |
| Feb 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.75 | $37.81 | +0.2% | +3.0% | -2.3% | -2.6% | +1.2% | +3.4% |
| Feb 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $37.75 | $37.81 | +0.2% | +3.0% | -2.3% | -2.6% | +1.2% | +3.4% |
| Feb 4 | JP Morgan | Maintains | Overweight → Overweight | — | $37.20 | $37.55 | +0.9% | +1.0% | +2.5% | -2.0% | +3.0% | -2.3% |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.50 | $40.70 | +0.5% | +2.7% | -1.4% | -1.5% | +1.7% | +0.9% |
| Nov 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.65 | $43.30 | +4.0% | +11.5% | -2.0% | -1.5% | +0.3% | -2.6% |
| Nov 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $40.39 | $38.27 | -5.2% | -4.3% | +5.2% | +2.5% | +11.5% | -2.0% |
| Nov 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $46.23 | $46.90 | +1.4% | +0.6% | -7.2% | -1.2% | -3.8% | +0.2% |
| Sep 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $44.79 | $45.25 | +1.0% | +1.9% | +3.0% | -1.7% | -2.8% | -0.3% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $36.21 | $36.63 | +1.2% | -1.2% | +3.9% | +4.1% | +4.9% | -0.7% |
| Aug 7 | JMP Securities | Maintains | Market Outperform → Market Outperform | — | $36.21 | $36.63 | +1.2% | -1.2% | +3.9% | +4.1% | +4.9% | -0.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 10, 2026 | Waddill William D.Dir | — | Sell | 9,000 | $107.68 | $969K | 7,825 | -0.01% | +1.27% |
| May 29, 2026 | Waddill William D.Dir | — | Sell | 9,000 | $99.64 | $897K | 7,825 | -1.78% | +0.67% |
| May 12, 2026 | PATEL DINESH V PH DDir/Off | President and CEO | Sell | 75,000 | $100.12 | $7.5M | 523,478 | -3.19% | +1.12% |
| May 12, 2026 | PATEL DINESH V PH DDir/Off | President and CEO | Sell | 75,000 | $100.12 | $7.5M | 523,478 | +3.93% | -2.35% |
| May 8, 2026 | Giraudo BryanDir | — | Sell | 5,130 | $100.00 | $513K | 12,695 | -3.43% | -1.41% |
| May 8, 2026 | Giraudo BryanDir | — | Sell | 6,000 | $100.00 | $600K | — | -3.43% | -1.41% |
| May 7, 2026 | Giraudo BryanDir | — | Sell | 12,000 | $100.07 | $1.2M | 6,000 | -3.43% | -1.41% |
| May 7, 2026 | Giraudo BryanDir | — | Sell | 36,000 | $100.14 | $3.6M | 27,825 | -3.43% | -1.41% |
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Farallon Capital Management Llc | 6,348,906 | $669M | New | Mar 2026 |
| 2 | Ubs Group Ag | 5,177,796 | $546M | Added | Mar 2026 |
| 3 | Rtw Investments, Lp | 5,059,053 | $533M | — | Mar 2026 |
| 4 | Vanguard Portfolio Management Llc | 3,481,211 | $367M | New | Mar 2026 |
| 5 | Janus Henderson Group Plc | 2,891,527 | $305M | New | Mar 2026 |
| 6 | Vanguard Capital Management Llc | 2,805,896 | $296M | New | Mar 2026 |
| 7 | Johnson & Johnson | 2,449,183 | $258M | — | Mar 2026 |
| 8 | Invesco Ltd. | 2,164,670 | $228M | Added | Mar 2026 |
| 9 | Citadel Advisors Llc | 1,551,900 | $164M | Added | Mar 2026 |
| 10 | Morgan Stanley | 1,758,048 | $154M | Added | Dec 2025 |
| 11 | Woodline Partners Lp | 1,414,173 | $149M | — | Mar 2026 |
| 12 | Bank Of America Corp /de/ | 1,295,434 | $137M | Added | Mar 2026 |
| 13 | Adar1 Capital Management, Llc | 994,119 | $105M | New | Mar 2026 |
| 14 | Hood River Capital Management Llc | 829,285 | $87M | New | Mar 2026 |
| 15 | Fmr Llc | 661,997 | $70M | Added | Mar 2026 |
| 16 | Marshall Wace, Llp | 628,075 | $66M | Reduced | Mar 2026 |
| 17 | Clearbridge Investments, Llc | 621,820 | $66M | Added | Mar 2026 |
| 18 | Alyeska Investment Group, L.p. | 593,197 | $63M | Added | Mar 2026 |
| 19 | Northern Trust Corp | 587,968 | $62M | Added | Mar 2026 |
| 20 | Pictet Asset Management Holding Sa | 529,631 | $46M | Reduced | Dec 2025 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$7.17B
Enterprise Value
$6.61B
P/E (TTM)
-55.05x
Forward P/E
34.93x
PEG Ratio
0.29x
P/B
11.67x
P/S
155.92x
P/FCF
127.94x
EV/EBITDA
—
Shares Out
63.6M
Financials (TTM)
Revenue
$46.0M
Net Income
-$130.1M
EBITDA
-$128.1M
Free Cash Flow
$56.1M
Op Cash Flow
$57.7M
EPS Basic
$-2.05
EPS Diluted
$-2.05
EPS Forward
$3.23
Gross Margin
97.3%
Op Margin
-343.6%
Net Margin
-282.8%
Balance Sheet
Total Assets
$669.9M
Total Liab.
$55.2M
Total Equity
$614.7M
Cash
$567.4M
LT Debt
$0
Book Value/Sh
$9.67
Debt/Equity
0.02x
Current Ratio
12.71
Quick Ratio
12.71
Returns & Growth
ROE
-21.2%
ROA
-19.5%
ROIC
-25.2%
Rev Growth YoY
-89.4%
EPS Growth YoY
-145.9%
Price Returns
2W
-5.7%
1M
+0.6%
3M
+8.1%
6M
+10.6%
12M
+109.7%
Technicals
52W High
$112.86
52W Low
$49.70
50d MA
$102.30
200d MA
$87.50
RSI (14)
66.40
ATR (14)
$4.89
Beta
2.11
Avg Volume
610K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$116.75
High
$121.00
Low
$108.00
Median
$119.00
Data updated apr 26, 2026 9:08pm
· Source: financialmodelingprep.com